Dyne Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
DYN Nasdaq 8731 https://www.dyne-tx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dyne Therapeutics Inc

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy - Mar 23rd, 2023 11:30 am
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference - Mar 20th, 2023 11:30 am
Dyne Therapeutics to Present at Upcoming Investor Conferences - Mar 7th, 2023 12:30 pm
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights - Mar 2nd, 2023 12:30 pm
How to chart anchored VWAP multiple time frames: Brian Shannon, CMT - Mar 1st, 2023 2:00 pm
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock - Feb 27th, 2023 9:40 pm
TipRanks ‘Perfect 10’ List: Strong Catalysts Confirm the Bull Thesis on These 2 Stocks - Feb 5th, 2023 10:03 am
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics - Jan 19th, 2023 1:23 pm
5 Stocks to Buy as the Drug Industry Bets Big on Innovation - Jan 18th, 2023 1:49 pm
All You Need to Know About Dyne Therapeutics, Inc. (DYN) Rating Upgrade to Strong Buy - Jan 10th, 2023 5:00 pm
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 12:30 pm
Does Dyne Therapeutics, Inc. (DYN) Have the Potential to Rally 84% as Wall Street Analysts Expect? - Dec 16th, 2022 2:55 pm
Here's Why Dyne Therapeutics, Inc. (DYN) Is a Great 'Buy the Bottom' Stock Now - Dec 9th, 2022 2:55 pm
Will Dyne Therapeutics (NASDAQ:DYN) Spend Its Cash Wisely? - Dec 8th, 2022 1:10 pm
Wall Street Analysts Predict a 141% Upside in Dyne Therapeutics, Inc. (DYN): Here's What You Should Know - Nov 30th, 2022 2:55 pm
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights - Nov 3rd, 2022 11:30 am
Dyne Therapeutics to Present at Investor Conferences in November - Nov 2nd, 2022 11:30 am
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy - Oct 31st, 2022 11:30 am
Dyne founder heads up new RNA-editing startup - Oct 12th, 2022 10:45 am
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress - Oct 11th, 2022 8:10 pm